Dyne Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
(technical difficulty) Thank you, everybody. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company Dyne, which are posted at the back of the room and also at the registration desk. So Dyne is developing targeted RNA medicines to treat muscular dystrophies. Now we have DYNE-101 for type one myotonic dystrophy in the clinic and also DYNE-251 for DMD.
Here with us today is Dyne's President and CEO, my good friend, Josh Brumm, Chief Medical Officer, Dr. Wildon Farwell, and I know this is going to be the trickiest one, so I am going to apologize beforehand, but Chief Scientific Officer, Oxana Beskrovnaya.
Thank you.
Questions & Answers
Okay, you're okay, so it's all right. So thank you, guys all for being with us today. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |